Israeli weight-loss pill stock soars despite detail-free announcement

Israel's Epitomee Medical announced a successful trial for its weight-loss pill; Despite not disclosing the results involving 279 participants, the company's stock rose by 80% at the end of the trading day
Adiel Eithan Mustaki|
Epitomee Medical, an Israeli pharmaceutical company, has reported a successful trial run with respect to their weight-loss pills, which triggered a huge rise in their stock, ending the trading day with 80% over the opening.
<< Follow Ynetnews on Facebook | Twitter | Instagram | TikTok >>
Read more:
The pill, upon swallowing, swells as it comes into contact with our digestive juices, making you believe you're full when you're actually not. After reporting its success, the company's market value soared to $101.4 million.
2 View gallery
Epitomee's new capsule
Epitomee's new capsule
Epitomee's new pill
(Photo: Epitomee Medical)
Said soaring occurred despite the company still withholding the results of the test itself, simply announcing it was "successful". Critical data such as average weight loss and deep statistical analysis according to groups have not been disclosed.
Medical trial success was pre-defined as a situation when 35% of trial subjects, totaling 279 individuals, experienced a weight loss of at least 5%. Epitomee asserts final data is forthcoming, following final data release from the outside contractor that both executes and supervises the trial.
With this medicine being designated as "Substantially equivalent" to a drug already on the market, Epitomee foresee final FDA approval and subsequent commercial release sometime during 2024.
2 View gallery
דיאטה בעקבות עודף משקל
דיאטה בעקבות עודף משקל
Weight loss trial results are successful, company says
(Photo: Shutterstock)
The fact of the matter is that the route in which "Substantially equivalent" medicine is released is rather streamlined and effortless compared to full FDA evaluation, which has triggered criticism as to how easy it is to insert "more of the same" into the American medicinal landscape, saturated as it is.
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.